MedPage Today5h
Major PBMs Inflated Drug Prices, Pocketing $7.3 Billion Along the Way, FTC Says
The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of ...
PBMs made billions marking up specialty drugs by more than 1,000 percent: FTC
The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying ...
New report accuses PBMs of driving up prescription drug costs
The Federal Trade Commission found Pharmacy Benefit Managers profited billions by raising the prices of "specialty drugs." ...
FTC Says UnitedHealth, CVS, Cigna Make Billions Via PBMs On Specialty Drugs
FTC report reveals significant markups by top PBMs on specialty drugs, driving $7.3 billion in revenue and raising costs for ...
STAT10h
Will PBM reform save pharmacies from closing?
Mattingly is an associate professor and vice chair of research in the Department of Pharmacotherapy at the University of Utah ...
FTC says PBMs inflated prices
The Federal Trade Commission accuses CVS, Cigna and UnitedHealth of artificially inflating prices on specialty generic drugs ...
Benefits Pro22h
FTC accuses big PBMs' pharmacies of collecting $5.9B in specialty drug markups
Margin expansion at Express Scripts, Caremark and Optum Rx increased by $336 million between 2017 and 2021, officials say.
Lawmaker may file bill to regulate PBMs: They’re managing the dollar
An Alabama lawmaker believes prescription care management should be a legislative priority during the upcoming session.
FTC report shows $7.3 billion in drug price inflation by leading pharmacy benefit managers
From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 ...
STAT5h
Pharmalittle: We’re reading about FTC criticizing PBMs, a NIH policy on access to medicines, and more
The FDC released a second highly critical report of PBMs, which may provide further impetus for legislative action to curb ...
ConsumerAffairs7h
Another FTC report is highly critical of pharmacy benefit managers
In the debate over the high cost of prescription drugs, pharmacy benefit managers are hotly contested. PBMs, the middlemen in ...